(Q37859955)

24 August 2017

1 reference

title

Visceral leishmaniasis: elimination with existing interventions (English)

1 reference

24 August 2017

visceral leishmaniasis

1 reference

Axel Kroeger

3

0 references

Shyam Sundar

5

object named as

Shyam Sundar

1 reference

24 August 2017

9

Dinesh Mondal

1 reference

24 August 2017

Greg Matlashewski

1

1 reference

24 August 2017

Byron Arana

2

1 reference

24 August 2017

Sujit Battacharya

4

1 reference

24 August 2017

Pradeep Das

6

1 reference

24 August 2017

Prabhat Kumar Sinha

7

1 reference

24 August 2017

Suman Rijal

8

1 reference

24 August 2017

Dan Zilberstein

10

1 reference

24 August 2017

Jorge Alvar

11

1 reference

24 August 2017

1 April 2011

1 reference

Lancet Infectious Diseases

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

4

1 reference

24 August 2017

322-325

1 reference

Complexities of assessing the disease burden attributable to leishmaniasis

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Leishmaniasis and poverty

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Advances in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Developments in the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Sterols of Leishmania species. Implications for biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Antifungal resistance in pathogenic fungi

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Combination therapy for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Ambisome plus miltefosine for Indian patients with kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

Control of phlebotomine sandflies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970320-0

7 January 2021

10.1016/S1473-3099(10)70320-0

Identifiers

DOI

1 reference

24 August 2017

1 reference